<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868283</url>
  </required_header>
  <id_info>
    <org_study_id>EBE-CN-050823</org_study_id>
    <nct_id>NCT00868283</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke</brief_title>
  <acronym>CASTA</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ever Neuro Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Excel PharmaStudies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>idv Datenanalyse und Versuchsplanung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ever Neuro Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigated the clinical efficacy and safety of a 10-day course of therapy with
      daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in
      patients with acute ischemic stroke. 1070 patients were randomized in this trial in 2
      parallel groups, one receiving Cerebrolysin, the control group receiving Placebo. Study drug
      will be given once daily by intravenous infusion for 10 consecutive days. Acetylsalicylic
      acid will be given orally, once daily throughout the study duration of 90 days as basic
      treatment. The clinical observation period for each patient will be 3 months and will include
      six clinical evaluation visits at Baseline (day 1) and on study days 2, 5, 10, 30 and 90.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>90 days after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>90 days after start of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NIH Stroke Scale</measure>
    <time_frame>90 days after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>90 days after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall mortality</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1071</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Cerebrolysin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% Saline Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <description>30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.</description>
    <arm_group_label>Cerebrolysin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline Solution</intervention_name>
    <description>30 ml will be given once daily by intravenous infusion for 10 consecutive days.</description>
    <arm_group_label>0.9% Saline Solution</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 85 years

          -  Focal neurological deficit

          -  Clinical diagnosis of acute hemispheric ischemic stroke

          -  CT or MRI results compatible with clinical diagnosis of acute hemispheric stroke

          -  NIH Stroke Scale Score between 6 and 22, both inclusive

          -  Functionally independent prior to stroke with a pre-stroke Rankin Score of 0 or 1

          -  Randomization and first treatment with the trial medication within 12h after stroke
             onset

          -  Informed consent given by the patient and/or the patient's legally acceptable
             representative

        Exclusion Criteria:

          -  Evidence on CT/MRI of acute or chronic intracerebral hemorrhage, SAH, AVM, cerebral
             aneurysm, or neoplasm

          -  Signs of herniation, increased intracranial pressure or likely etiology other than
             brain ischemia at baseline CT scan

          -  Patients with a substantial decrease of consciousness or alertness at the time of
             randomization, defined as score of 2 or more one of the NIH Stroke Scale questions 1a.

          -  Neurological signs and symptoms that improve rapidly during screening and are likely
             to resolve completely within 24h

          -  Severe coexisting systemic disease that significantly limits life expectancy

          -  Systolic blood pressure over 220 mmHg or diastolic blood pressure over 120 mmHg on
             repeated measurement (interval of 30 min) prior to study entry

          -  Severe congestive heart failure or presentation with acute myocardial infarction at
             study entry

          -  Epilepsy or epileptic seizures at onset of stroke

          -  Pre-existing disorders or conditions that would impair interpretation of neurological
             assessment (eg. severe dementia, severe psychiatric illnesses, etc).

          -  Concomitant treatment with other neuroprotective or nootropic drugs (e.g. piracetam,
             citicoline, investigational neuroprotective substances)

          -  Patients which cannot tolerate or have contraindication to aspirin or Cerebrolysin
             treatment

          -  Concomitant treatment with substances that have a dilative effect on blood vessels
             like naftidrofuryl, cinnarizine, flunarizine or nimodipine

          -  Pregnancy and lactation period; for women with child-bearing potential a negative
             pregnancy test is required

          -  Participation in a clinical trial with an investigational drug in the past 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Novak, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EVER Neuro Pharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhen Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital, affiliated Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mudanjiang 1st people Hospital</name>
      <address>
        <city>Mudanjiang</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mudanjiang 2nd people Hospital</name>
      <address>
        <city>Mudanjiang</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anhui Shengli Hospital</name>
      <address>
        <city>Anhui</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anshan hospital</name>
      <address>
        <city>Anshan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baotou Center Hospital</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third hospital, affiliated Neimenggu Medical University (Bao Gang hospital)</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First hospital, affiliated Peking University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friendship Hospital, affiliated Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sino-Japanese Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou 2nd People's Hospital</name>
      <address>
        <city>Canton</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First hospital, affiliated Bethune Medical University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital Affiliated Bethune Medical University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, affiliated Hunan Medical University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chengdu 2nd People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital, affiliated Huaxi Medical University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Province People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital, affiliated Chongqing Med. University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalian Center Hospital</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalian third people Hospital</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital, affiliated Wenzhou Med. University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First hospital, affiliated Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FuJian Shengli Hospital</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital, affiliated Shantou Medical University</name>
      <address>
        <city>Guandong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou red cross hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital, affiliated Medical college Zhejing University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 4st Hospital affiliated Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital, affiliated Kunming Med. University</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yinchuan People's Hospital</name>
      <address>
        <city>Mudanjiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing PLA General Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital, affiliated Qingdao Medical University</name>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, affiliated Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, affiliated Second Medical University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, affiliated Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai 6th People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinhua hospital of Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, affiliated Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei Province People's Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin First Medical Center</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Union Medicine Centre</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital, affiliated Huazhong science and technology University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First hospital, affiliated NingXia Mededical University</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First hospital, affiliated Henan Medical University</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-west neo medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyung-hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>July 6, 2011</last_update_submitted>
  <last_update_submitted_qc>July 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Philipp Novak</name_title>
    <organization>EVER Neuro Pharma</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

